Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13565844 | 1.00 | MAPT (0.40) | MAPTLRRK2CNR2HTR2ADRD3 | |
| SCHEMBL13565789 | 0.92 | LRRK2 (0.40) | MAPTLRRK2CNR2HTR2ADRD3 | |
| SCHEMBL17090254 | 0.92 | LRRK2 (0.40) | MAPTLRRK2CNR2HTR2ADRD3 | |
| SCHEMBL13564738 | 0.92 | MAPT (0.43) | MAPTLRRK2CNR2HTR2ADRD3 | |
| SCHEMBL13565140 | 0.92 | MAPT (0.43) | MAPTLRRK2CNR2HTR2ADRD3 | |
| SCHEMBL17089987 | 0.92 | MAPT (0.43) | MAPTLRRK2CNR2HTR2ADRD3 | |
| SCHEMBL11936149 | 0.92 | MAPT (0.43) | MAPTLRRK2CNR2HTR2ADRD3 | |
| SCHEMBL11936184 | 0.86 | MAPT (0.43) | MAPTLRRK2HTR2ADRD3 | |
| SCHEMBL13565767 | 0.85 | ALDH1A1 (0.39) | MAPTCNR2ALDH1A1ALDH3A1 | |
| SCHEMBL17090219 | 0.85 | MAPT (0.44) | MAPTLRRK2HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139518-B2 | Amine derivative having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |